The Korean journal of internal medicine

  • 제30권1호
  • /
  • Pages.23-26
  • /
  • 2015
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?

  • Kim, Ji Hoon (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Lee, June Sung (Department of Internal Medicine, Inje University Ilsan Paik Hospital)
  • 투고 : 2014.11.24
  • 심사 : 2014.11.28
  • 발행 : 2015.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455. https://doi.org/10.1056/NEJMoa0802878
  2. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475. https://doi.org/10.1016/S0140-6736(12)61425-1
  3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531. https://doi.org/10.1056/NEJMoa033364
  4. Seto WK, Liu K, Fung J, et al. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther 2012;17:1255-1262. https://doi.org/10.3851/IMP2335
  5. Kim HJ, Cho JY, Kim YJ, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med 2015;30:32-41. https://doi.org/10.3904/kjim.2015.30.1.32
  6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185. https://doi.org/10.1016/j.jhep.2012.02.010
  7. Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355-362.
  8. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109-162. https://doi.org/10.3350/cmh.2012.18.2.109
  9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662. https://doi.org/10.1002/hep.23190
  10. van Bommel F, de Man RA, Wedemeyer H, et al. Longterm efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80. https://doi.org/10.1002/hep.23246
  11. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014;146:980-988. https://doi.org/10.1053/j.gastro.2013.12.028
  12. Lim YS, Yoo BC, Byun KS, et al. Randomized trial of tenofovir monotherapy versus tenofovir plus entecavir combination therapy in chronic hepatitis B patients with genotypic resistance mutations to adefovir. J Hepatol 2014;60(1 Suppl):S431.
  13. Kwon SY, Yoo BC, Byun KS, et al. Tenofovir is effective alone or with entecavir in entecavir-resistant patients with chronic-hepatitis B virus infection: multicenter randomized trial. Clin Mol Hepatol 2014;20:S5.

피인용 문헌

  1. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy vol.22, pp.2, 2015, https://doi.org/10.3350/cmh.2015.0053
  2. 일 지역 대학생의 흡연 실태와 흡연에 영향을 미치는 요인에 관한 연구 vol.17, pp.8, 2015, https://doi.org/10.5762/kais.2016.17.8.465